NCT07002242View on ClinicalTrials.gov

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

August 25, 2022

Study Completion Date

February 21, 2023

Conditions
Healthy
Interventions
DRUG

Azvudine tablets(FNC) and Aluvia

FNC 3 mg each time, 1 time a day, orally, for 5 consecutive days. Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.

DRUG

Azvudine tablets(FNC)

FNC: 3 mg each time, 1 time a day, orally, for 5 consecutive days

DRUG

Aluvia

Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.

Trial Locations (1)

Unknown

Tianjin People's Hospital, Tianjin

All Listed Sponsors
lead

Henan Genuine Biotech Co., Ltd.

INDUSTRY